Trial · NCT00700102
A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.
NCT00700102, Phase 3, Completed, Hoffmann-La Roche; results first posted 2015-07-30
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer. Trials, record NCT00700102. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00700102
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.
- NCT number
- NCT00700102
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 820 participants, actual
- Lead sponsor
- Hoffmann-La Roche
- Conditions
- Colorectal Cancer
- Interventions
- Chemotherapy, Bevacizumab
- First posted
- 2008-06-18
- Last updated
- 2015-07-30
- Other registries' IDs
- eudract:2006-004634-32
- Results first posted
- 2015-07-30
- Limitations and caveats
Patients in the study who were randomized to receive bevacizumab could continue to receive bevacizumab following discontinuation of chemotherapy, thereby minimizing any potential bias introduced by differential follow-up time in the treatment arms.
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Survival: Time From Randomization to Death From Any Cause | within 6.5 years | |
| Secondary | Overall Survival: Months From Time of First Line Therapy | within approximately 9.6 years | |
| Secondary | Participants With Progression Free Survival Event | within 6.5 years | |
| Secondary | Progression Free Survival: Time to Event | within 6.5 years | |
| Secondary | Response Rate: Percentage of Participants With Best Overall Response, Defined as Confirmed Complete Response (CR) or Partial Response (PR) According to RECIST Criteria | within 6.5 years | |
| Secondary | Response Rate: Participants With Response Status Based on RECIST Criteria | within 6.5 years | Response Evaluation Criteria In Solid Tumors (RECIST) is a set of published rules that define when tumors in cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progress") during treatment. |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Overall Survival: Time From Randomization to Death From Any Cause | within 6.5 years | Intention to treat | months | MEDIAN |
| SECONDARY | Overall Survival: Months From Time of First Line Therapy | within approximately 9.6 years | months | MEDIAN | |
| SECONDARY | Participants With Progression Free Survival Event | within 6.5 years | Unstratified intention to treat population | participants | NUMBER |
| SECONDARY | Progression Free Survival: Time to Event | within 6.5 years | Unstratified intention to treat population | Months | MEDIAN |
| SECONDARY | Response Rate: Percentage of Participants With Best Overall Response, Defined as Confirmed Complete Response (CR) or Partial Response (PR) According to RECIST Criteria | within 6.5 years | Participants with measurable disease | percentage of participants | NUMBER |
| SECONDARY | Response Rate: Participants With Response Status Based on RECIST Criteria | within 6.5 years | Participants with measurable disease | percentage of participants | NUMBER |
Source ClinicalTrials.gov
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival: Time From Randomization to Death From Any Cause | Chemotherapy | 9.8 | 95% Confidence Interval 9 to 11 | months | |
| Overall Survival: Time From Randomization to Death From Any Cause | Chemotherapy + Bevacizumab | 11.2 | 95% Confidence Interval 10 to 12 | months | |
| Overall Survival: Months From Time of First Line Therapy | Chemotherapy | 22.5 | 95% Confidence Interval 21 to 25 | months | |
| Overall Survival: Months From Time of First Line Therapy | Chemotherapy + Bevacizumab | 23.9 | 95% Confidence Interval 22 to 26 | months | |
| Participants With Progression Free Survival Event | Chemotherapy | 394 | participants | ||
| Participants With Progression Free Survival Event | Chemotherapy + Bevacizumab | 386 | participants | ||
| Progression Free Survival: Time to Event | Chemotherapy | 4.1 | Full Range 0 to 27 | Months | |
| Progression Free Survival: Time to Event | Chemotherapy + Bevacizumab | 5.7 | Full Range 0 to 38 | Months | |
| Response Rate: Percentage of Participants With Best Overall Response, Defined as Confirmed Complete Response (CR) or Partial Response (PR) According to RECIST Criteria | Chemotherapy | 3.9 | 95% Confidence Interval 2.3 to 6.3 | percentage of participants | |
| Response Rate: Percentage of Participants With Best Overall Response, Defined as Confirmed Complete Response (CR) or Partial Response (PR) According to RECIST Criteria | Chemotherapy + Bevacizumab | 5.4 | 95% Confidence Interval 3.4 to 8.1 | percentage of participants |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 results by groupParticipant flow10
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Chemotherapy | 411 | |
| Overall Study | STARTED | Chemotherapy + Bevacizumab | 409 | |
| Overall Study | Intention to Treat | Chemotherapy | 410 | |
| Overall Study | Intention to Treat | Chemotherapy + Bevacizumab | 409 | |
| Overall Study | Received at Least One Dose | Chemotherapy | 407 | |
| Overall Study | Received at Least One Dose | Chemotherapy + Bevacizumab | 403 | |
| Overall Study | COMPLETED | Chemotherapy | 9 | |
| Overall Study | COMPLETED | Chemotherapy + Bevacizumab | 14 | |
| Overall Study | NOT COMPLETED | Chemotherapy | 402 | |
| Overall Study | NOT COMPLETED | Chemotherapy + Bevacizumab | 395 |
Source ClinicalTrials.gov
Adverse events388
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhoea | Gastrointestinal disorders | Chemotherapy | 177 | 409 | 333 |
| other | Diarrhoea | Gastrointestinal disorders | Chemotherapy + Bevacizumab | 233 | 401 | 471 |
| other | Nausea | Gastrointestinal disorders | Chemotherapy | 170 | 409 | 294 |
| other | Nausea | Gastrointestinal disorders | Chemotherapy + Bevacizumab | 178 | 401 | 340 |
| other | Vomiting | Gastrointestinal disorders | Chemotherapy | 104 | 409 | 162 |
| other | Vomiting | Gastrointestinal disorders | Chemotherapy + Bevacizumab | 119 | 401 | 188 |
| other | Abdominal pain | Gastrointestinal disorders | Chemotherapy | 76 | 409 | 91 |
| other | Abdominal pain | Gastrointestinal disorders | Chemotherapy + Bevacizumab | 89 | 401 | 126 |
| other | Constipation | Gastrointestinal disorders | Chemotherapy | 74 | 409 | 96 |
| other | Constipation | Gastrointestinal disorders | Chemotherapy + Bevacizumab | 82 | 401 | 120 |
1 to 10 of 388Source ClinicalTrials.gov
See all 388 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Chemotherapy | ||
| Total, all-cause mortality | Chemotherapy + Bevacizumab | ||
| Total, other adverse events | Chemotherapy | 379 | 409 |
| Total, other adverse events | Chemotherapy + Bevacizumab | 382 | 401 |
| Total, serious adverse events | Chemotherapy | 137 | 409 |
| Total, serious adverse events | Chemotherapy + Bevacizumab | 130 | 401 |
Source ClinicalTrials.gov
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Chemotherapy vs Chemotherapy + Bevacizumab: Participants With Progression Free Survival Event | Trial comparisons |
| Chemotherapy vs Chemotherapy + Bevacizumab: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00700102
GET https://conductscience.org/api/trials/v1/NCT00700102/events?page=2